← Back to Screener
Galectin Therapeutics Inc. (GALT)
Price$2.33
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-67.26%
Price vs S&P 500 (4W)10.96%
VGM Score39.65
Market Capitalization$153.45M
All Metrics
Book Value / Share (Quarterly)$0.04
P/TBV (Annual)20.45x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.30
Price vs S&P 500 (YTD)-52.15%
EPS (TTM)$-0.41
10-Day Avg Trading Volume0.35M
EPS Excl Extra (TTM)$-0.41
EPS (Annual)$-0.48
ROI (Annual)-96.40%
Cash / Share (Quarterly)$0.21
ROA (Last FY)-157.87%
EBITD / Share (TTM)$-0.25
ROE (5Y Avg)-571.52%
Cash Flow / Share (Annual)$-0.37
P/B Ratio58.57x
P/B Ratio (Quarterly)46.88x
Net Income / Employee (Annual)$-3,426,200
Net Interest Coverage (TTM)-1.87x
ROA (TTM)-164.69%
EPS Incl Extra (Annual)$-0.48
Current Ratio (Annual)2.42x
Quick Ratio (Quarterly)1.93x
3-Month Avg Trading Volume0.32M
52-Week Price Return79.23%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.17
52-Week High$7.13
EPS Excl Extra (Annual)$-0.48
Tangible BV CAGR (5Y)-3.39%
26-Week Price Return-59.34%
Quick Ratio (Annual)2.21x
13-Week Price Return-23.10%
Total Debt / Equity (Annual)11.09x
Current Ratio (Quarterly)2.15x
Enterprise Value$275.05M
Book Value / Share Growth (5Y)-34.45%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.27
3-Month Return Std Dev86.18%
Net Income / Employee (TTM)$-2,916,800
ROE (Last FY)-1165.27%
Net Interest Coverage (Annual)-1.63x
EPS Basic Excl Extra (Annual)$-0.48
Total Debt / Equity (Quarterly)11.09x
EPS Incl Extra (TTM)$-0.41
ROI (TTM)-116.07%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.17
Price vs S&P 500 (52W)54.87%
Year-to-Date Return-43.99%
5-Day Price Return-10.73%
EPS Normalized (Annual)$-0.48
ROA (5Y Avg)-165.51%
Month-to-Date Return-7.54%
EBITD / Share (Annual)$-0.31
LT Debt / Equity (Annual)11.09x
ROI (5Y Avg)-357.74%
LT Debt / Equity (Quarterly)11.09x
EPS Basic Excl Extra (TTM)$-0.41
P/TBV (Quarterly)20.45x
P/B Ratio (Annual)46.88x
Book Value / Share (Annual)$0.04
Price vs S&P 500 (13W)-31.36%
Beta0.58x
Revenue / Share (TTM)$0.00
ROE (TTM)-258.62%
52-Week Low$1.27
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.08est. -0.06
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GALTGalectin Therapeutics Inc. | — | — | D | $2.33 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing belapectin, a galectin-3 inhibitor targeting liver fibrosis, cancer, and related diseases. Preclinical studies have demonstrated belapectin's potential to reverse liver fibrosis and cirrhosis, addressing significant unmet medical needs.